Table 2.
Summary of identified CINV risk factors based on multivariate analysis using backward elimination
| Factor | Overall (0–120 h) | Acute (0–24 h) | Delayed (24–120 h) | Extended overall (0–168 h) | Extended delayed (24–168 h) | Beyond delayed (120–168 h) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| Overall population | ||||||||||||
| Age (≥ 55/ < 55) | – | – | 1.774 (1.062–2.962) | 0.028 | – | – | – | – | – | – | – | – |
| Sex (male/female) | 1.528 (1.114–2.095) | 0.009 | 2.434 (1.587–3.733) | < 0.001 | 1.529 (1.110–2.107) | 0.009 | 1.512 (1.111–2.059) | 0.009 | 1.455 (1.063–1.991) | 0.019 | – | – |
| Performance status (0/1) | 1.404 (1.097–1.798) | 0.007 | – | – | 1.417 (1.102–1.823) | 0.007 | 1.336 (1.049–1.701) | 0.019 | 1.329 (1.040–1.697) | 0.023 | – | – |
| Drinking history (yes/no or rarely) | 1.663 (1.283–2.155) | < 0.001 | 1.854 (1.176–2.923) | 0.008 | 1.746 (1.339–2.278) | < 0.001 | 1.733 (1.348–2.227) | < 0.001 | 1.780 (1.378–2.298) | < 0.001 | – | – |
| Smoking history (yes/no) | 1.466 (1.038–2.069) | 0.030 | – | – | 1.514 (1.068–2.145) | 0.020 | 1.443 (1.028–2.025) | 0.034 | 1.454 (1.032–2.047) | 0.032 | – | – |
| Motion sickness (no/yes) | 1.524 (1.047–2.219) | 0.028 | 1.750 (1.028–2.978) | 0.039 | 1.659 (1.138–2.420) | 0.009 | – | – | 1.521 (1.047–2.210) | 0.028 | – | – |
| Pregnancy-related vomiting (no/yes) | – | – | – | – | – | – | – | – | – | – | – | – |
| Cancer type (other/lung) | – | – | – | – | – | – | – | – | – | – | – | – |
| CDDP dose (< 80 mg/m2/ ≥ 80 mg/m2) | – | – | 2.175 (1.417–3.338) | < 0.001 | – | – | – | – | – | – | – | – |
| NK-1RA (placebo/FosNTP 235 mg) | 0.373 (0.262–0.531) | < 0.001 | 0.253 (0.146–0.438) | < 0.001 | 0.365 (0.255–0.523) | < 0.001 | 0.370 (0.261–0.523) | < 0.001 | 0.370 (0.260–0.526) | < 0.001 | ||
| Treatment failure in 0–120 h (no/yes) | – | – | – | – | – | – | – | – | – | – | 20.951 (14.407–30.466) | < 0.001 |
| FosNTP 235 mg group | ||||||||||||
| Age (≥ 55/ < 55) | – | – | 2.641 (1.126–6.191) | 0.026 | – | – | – | – | – | – | – | – |
| Sex (male/female) | – | – | – | – | – | – | – | – | – | – | – | – |
| Performance status(0/1) | – | – | – | – | – | – | – | – | – | – | – | – |
| Drinking history (yes/no or rarely) | 2.017 (1.317–3.089) | 0.001 | – | – | 2.172 (1.399–3.374) | < 0.001 | 2.049 (1.359–3.090) | < 0.001 | 2.177 (1.425–3.326) | < 0.001 | – | – |
| Smoking history (yes/no) | 1.842 (1.144–2.967) | 0.012 | – | – | 1.860 (1.149–3.012) | 0.012 | 1.900 (1.194–3.022) | 0.007 | 1.798 (1.120–2.886) | 0.015 | – | – |
| Motion sickness (no/yes) | 1.901 (1.082–3.342) | 0.026 | 2.045 (1.160–3.606) | 0.013 | – | – | 1.785 (1.016–3.138) | 0.044 | – | – | ||
| Pregnancy-related vomiting (no/yes) | – | – | – | – | – | – | – | – | – | – | – | – |
| Cancer Type (other/lung) | – | – | – | – | – | – | – | – | – | – | – | – |
| CDDP dose (< 80 mg/m2/ ≥ 80 mg/m2) | – | – | 2.659 (1.124–6.292) | 0.026 | – | – | – | – | – | – | – | – |
| Treatment failure in 0–120 h (no/yes) | – | – | – | – | – | – | – | – | – | – | 34.184 (17.262–67.696) | < 0.001 |
| FosAPR group | ||||||||||||
| Age (≥ 55/ < 55) | – | – | – | – | – | – | – | – | – | – | – | – |
| Sex (male/female) | – | – | 3.479 (1.610–7.518) | 0.002 | – | – | 2.351 (1.453–3.804) | < 0.001 | 2.446 (1.498–3.994) | < 0.001 | – | – |
| Performance status (0/1) | – | – | – | – | – | – | – | – | – | – | – | – |
| Drinking history (yes/no or rarely) | – | – | – | – | – | – | – | – | – | – | – | – |
| Smoking history (yes/no) | 2.160 (1.268–3.679) | 0.005 | – | – | 2.434 (1.423–4.166) | 0.001 | – | – | – | – | – | – |
| Motion sickness (no/yes) | 2.181 (1.049–4.534) | 0.037 | – | – | 2.422 (1.159–5.061) | 0.019 | – | – | 2.143 (1.023–4.489) | 0.043 | – | – |
| Pregnancy-related vomiting (no/yes) | – | – | – | – | – | – | – | – | – | – | – | – |
| Cancer type (other/lung) | – | – | – | – | – | – | – | – | – | – | – | – |
| CDDP dose (< 80 mg/m2/ ≥ 80 mg/m2) | – | – | – | – | – | – | – | – | – | – | – | – |
| Treatment failure in 0–120 h (no/yes) | – | – | – | – | – | – | – | – | – | – | 16.437 (8.806–30.681) | < 0.001 |
Data were obtained from the full analysis set
h hours, OR odds ratio, CI confidence interval, CDDP cisplatin, NK-1RA neurokinin 1 receptor antagonist, FosAPR fosaprepitant, FosNTP fosnetupitant